A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin
Copyright © 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved..
BACKGROUND AIMS: Intensified immunosuppressive prophylaxis for graft-versus-host disease (GVHD) may be toxic and therefore warranted only in patients at high risk of developing GVHD. In patients who underwent allogeneic hematopoietic cell transplant at the authors' center, high serum soluble IL-2 receptor alpha (sIL-2Rα) and low IL-15 levels on day 7 post-transplant were found to predict a high risk of developing clinically significant GVHD (sGVHD), defined as grade 2-4 acute GVHD or moderate to severe chronic GVHD.
METHODS: This was a prospective, phase 2 trial in which high-risk patients (serum sIL-2Rα >4500 ng/L or IL-15 <31 ng/L) received rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant. Controls consisted of patients who had their sIL-2Rα/IL-15 levels measured but did not participate in the trial. A total of 68 trial patients and 143 controls were accrued to this study. The primary endpoint was incidence of sGVHD.
RESULTS: There was a reduction in sGVHD in high-risk trial patients (received day 8 ATG) compared with high-risk controls (did not receive day 8 ATG) (sub-hazard ratio [SHR] = 0.48, P < 0.05). There was no significant difference between the groups in overall survival or relapse; however, there was a greater incidence of non-GVHD-associated non-relapse mortality in high-risk trial patients (SHR = 3.73, P < 0.05), mostly related to infections. This may be due in part to the biomarkers ineffectively stratifying GVHD risk.
CONCLUSIONS: Pre-emptive ATG therapy is both feasible and effective at reducing sGVHD without increasing relapse. Further mitigation strategies are needed to reduce the risk of infection associated with intensified GVHD prophylaxis. This study was registered at ClinicalTrials.gov (NCT01994824).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Cytotherapy - 23(2021), 11 vom: 06. Nov., Seite 1007-1016 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khanolkar, Rutvij A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ATG |
|---|
| Anmerkungen: |
Date Completed 28.10.2021 Date Revised 28.10.2021 published: Print-Electronic ClinicalTrials.gov: NCT01994824 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcyt.2021.06.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329172921 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329172921 | ||
| 003 | DE-627 | ||
| 005 | 20231225204533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcyt.2021.06.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329172921 | ||
| 035 | |a (NLM)34373186 | ||
| 035 | |a (PII)S1465-3249(21)00711-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khanolkar, Rutvij A |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2021 | ||
| 500 | |a Date Revised 28.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01994824 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND AIMS: Intensified immunosuppressive prophylaxis for graft-versus-host disease (GVHD) may be toxic and therefore warranted only in patients at high risk of developing GVHD. In patients who underwent allogeneic hematopoietic cell transplant at the authors' center, high serum soluble IL-2 receptor alpha (sIL-2Rα) and low IL-15 levels on day 7 post-transplant were found to predict a high risk of developing clinically significant GVHD (sGVHD), defined as grade 2-4 acute GVHD or moderate to severe chronic GVHD | ||
| 520 | |a METHODS: This was a prospective, phase 2 trial in which high-risk patients (serum sIL-2Rα >4500 ng/L or IL-15 <31 ng/L) received rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant. Controls consisted of patients who had their sIL-2Rα/IL-15 levels measured but did not participate in the trial. A total of 68 trial patients and 143 controls were accrued to this study. The primary endpoint was incidence of sGVHD | ||
| 520 | |a RESULTS: There was a reduction in sGVHD in high-risk trial patients (received day 8 ATG) compared with high-risk controls (did not receive day 8 ATG) (sub-hazard ratio [SHR] = 0.48, P < 0.05). There was no significant difference between the groups in overall survival or relapse; however, there was a greater incidence of non-GVHD-associated non-relapse mortality in high-risk trial patients (SHR = 3.73, P < 0.05), mostly related to infections. This may be due in part to the biomarkers ineffectively stratifying GVHD risk | ||
| 520 | |a CONCLUSIONS: Pre-emptive ATG therapy is both feasible and effective at reducing sGVHD without increasing relapse. Further mitigation strategies are needed to reduce the risk of infection associated with intensified GVHD prophylaxis. This study was registered at ClinicalTrials.gov (NCT01994824) | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ATG | |
| 650 | 4 | |a GVHD | |
| 650 | 4 | |a allogeneic HCT | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a pre-emptive therapy | |
| 650 | 7 | |a Antilymphocyte Serum |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Kalra, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Kinzel, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Pratt, Laura M |e verfasserin |4 aut | |
| 700 | 1 | |a Dharmani-Khan, Poonam |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhry, Ahsan |e verfasserin |4 aut | |
| 700 | 1 | |a Williamson, Tyler S |e verfasserin |4 aut | |
| 700 | 1 | |a Daly, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Don G |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Faisal M |e verfasserin |4 aut | |
| 700 | 1 | |a Storek, Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytotherapy |d 1999 |g 23(2021), 11 vom: 06. Nov., Seite 1007-1016 |w (DE-627)NLM118333852 |x 1477-2566 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:11 |g day:06 |g month:11 |g pages:1007-1016 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcyt.2021.06.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 11 |b 06 |c 11 |h 1007-1016 | ||